Evaluating fracture risk in patients with bone metastases from cancer
Generation of Synthetic Patient Data (RAW) for Risk Evaluation of Bone Metastases Derived From Carcinoma
This study looks at medical records of cancer patients with bone metastases to see if it can find ways to predict their risk of fractures.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Istituto Ortopedico Rizzoli Academic / other |
| Locations | 1 site (Bologna, Emilia-Romagna) |
| Trial ID | NCT06524843 on ClinicalTrials.gov |
What this trial studies
This observational study analyzes medical records, radiological imaging, and histological data of approximately 750 patients treated for bone metastases at the Rizzoli Institute from 2010 to 2022. The goal is to develop a prediction model for assessing fracture risk in these patients based on their clinical and imaging data. By reviewing historical patient information, the study aims to identify factors that contribute to fracture risk in individuals with bone metastases. This approach could enhance understanding of patient outcomes and inform clinical decision-making.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with bone metastases from any type of carcinoma.
Not a fit: Patients who do not have available imaging or clinical data, or who do not meet the inclusion criteria, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable prediction model for fracture risk, helping to improve patient management and treatment strategies.
How similar studies have performed: While there have been studies on fracture risk in cancer patients, this specific approach of utilizing a comprehensive historical data review for prediction modeling is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of bone metastasis from carcinoma, regardless of the type of carcinoma, and of the number and location of the metastases * Availability of imaging and clinical data * Availability of at least one follow-up during the last 12 months form diagnosis Exclusion Criteria: * At least one inclusion creteria not met
Where this trial is running
Bologna, Emilia-Romagna
- IRCCS Istituto Ortopedico Rizzoli — Bologna, Emilia-Romagna, Italy (Recruiting)
Study contacts
- Study coordinator: Costantino Errani, MD
- Email: costantino.errani@ior.it
- Phone: 0516366
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.